Market Research Report
Autologous Cell Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
|Published by||Mordor Intelligence LLP||Product code||921873|
|Published||Content info||112 Pages
Delivery time: 2-3 business days
|Autologous Cell Therapy Market - Growth, Trends, and Forecast (2020 - 2025)|
|Published: January 1, 2020||Content info: 112 Pages||
The Autologous Cell Therapy market studied was anticipated to grow with a CAGR of 15.9%, during the forecast period. The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, a blood disorder, and others. A rise in the population suffering from chronic diseases is also propelling the demand for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future. As per the CDC (Centers for Disease Control and Prevention) estimates Sickel Cell Disease (SCD) affects around 100,000 Americas annually. And there are few more factors which are playing crucial roles in taking the autologous cell therapy market to the next level, among them one is on-going drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market.
Autologous cell therapy (ACT) is a groundbreaking therapy that uses the cells of an individual that are grown and expanded outside of the body and reintegrated into the donor.
Bone Marrow Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, a blood disorder, autoimmune diseases, and other diseases and the availability of advanced healthcare infrastructure among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer and other chronic diseases, along with the rising geriatric population and developments related to stem cell therapy and rising demand for biotechnological practices in the country, is anticipated to further drive the demand in this region.
The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., and Opexa Therapeutics.